Therapeutic miRNA and siRNA: Moving from Bench to Clinic as Next Generation Medicine  Chiranjib Chakraborty, Ashish Ranjan Sharma, Garima Sharma, C. George Priya Doss, Sang-Soo Lee  Molecular Therapy - Nucleic Acids  Volume 8, Pages 132-143 (September 2017) DOI: 10.1016/j.omtn.2017.06.005 Copyright © 2017 The Authors Terms and Conditions

Figure 1 miRNA and siRNA Patents (A) Total number of keyword searches (“microRNA” and “siRNA”) performed in both the US patent search database and the European patent office database. (B) Number of patents in “microRNA” and “siRNA” in case of the different diseases. (C) Number of patents in “microRNA” and “siRNA” in event of the different type of cancers. Molecular Therapy - Nucleic Acids 2017 8, 132-143DOI: (10.1016/j.omtn.2017.06.005) Copyright © 2017 The Authors Terms and Conditions

Figure 2 List of Biopharmaceutical Companies Involved in miRNA and siRNA Therapeutics Different significant biopharmaceutical companies with their year of establishment since 1983 to 2017 that are involved in the development of the therapeutic miRNA and siRNA molecules. Molecular Therapy - Nucleic Acids 2017 8, 132-143DOI: (10.1016/j.omtn.2017.06.005) Copyright © 2017 The Authors Terms and Conditions

Figure 3 Status of Various miRNA and siRNA Therapeutics under Clinical Trials (Top left panel) Different siRNA molecules that are in a clinical trial and their status of clinical trial. (Top right panel) Different miRNAs molecules that are in preclinical and/or clinical trial and their status of clinical trial. (Bottom panel) Different important issues related to ADME during development of miRNA- and siRNA-based therapeutics molecules. Molecular Therapy - Nucleic Acids 2017 8, 132-143DOI: (10.1016/j.omtn.2017.06.005) Copyright © 2017 The Authors Terms and Conditions